DermTech Enters Into Agreement with Blue Cross Blue Shield of Texas
DermTech, Inc. (NASDAQ: DMTK) has partnered with Blue Cross Blue Shield of Texas to offer its Pigmented Lesion Assay (PLA) to approximately 6 million members. Effective from February 1, 2021, the PLA—a non-invasive test for early melanoma detection—will be accessible as an in-network option for several BCBSTX plans. The PLA boasts a 99% negative predictive value, significantly minimizing the risk of missed melanoma cases. DermTech aims to enhance patient access to this transformative test, reinforcing its commitment to precision dermatology.
- Contract with Blue Cross Blue Shield of Texas for PLA availability to 6 million members.
- PLA has a 99% negative predictive value, indicating high accuracy in melanoma detection.
- None.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has contracted, effective 2/1/2021, with Blue Cross Blue Shield of Texas (“BCBSTX”) to make DermTech’s Pigmented Lesion Assay (“PLA”) available to its approximately 6 million members in the State of Texas.
DermTech’s gene expression-based PLA for the early detection of melanoma is now available as an in-network option for Blue Cross Blue Shield of Texas’ Blue Essential, Traditional Indemnity and PPO/POS membership.
DermTech’s PLA is the first non-invasive gene expression test for the early detection of melanoma. Studies have shown that the PLA has a
“We are happy to announce our test as an in-network option for our current users of the PLA. This agreement with BCBSTX shows DermTech’s commitment to making its transformative PLA test accessible to more patients,” said Dan Visage, Senior Vice President of Payor Access at DermTech.
About DermTech:
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.
Forward-Looking Statements:
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness and commercialization of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10‑Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005839/en/
FAQ
What is the Pigmented Lesion Assay (PLA) offered by DermTech?
When did DermTech's PLA become available through Blue Cross Blue Shield of Texas?
What is the significance of the 99% negative predictive value of DermTech’s PLA?
How many members of Blue Cross Blue Shield of Texas will have access to DermTech’s PLA?
